Cobratoxin

PDB 1ctx EBI

Cobratoxin is a potent neurotoxin derived from the venom of the Naja genus, commonly known as cobras. It is a member of the three-finger toxin family, which is characterized by its unique three-fingered structure. Cobratoxin is known for its ability to bind to nicotinic acetylcholine receptors, leading to paralysis and potentially death.

Structure and Function

Cobratoxin is a polypeptide consisting of 71 amino acids. Its structure is stabilized by four disulfide bridges, which contribute to its high stability and resistance to enzymatic degradation. The three-finger structure allows it to interact specifically with the nicotinic acetylcholine receptors at the neuromuscular junction.

Mechanism of Action

Cobratoxin exerts its effects by binding to the nicotinic acetylcholine receptors on the postsynaptic membrane of the neuromuscular junction. This binding inhibits the action of acetylcholine, a neurotransmitter responsible for muscle contraction. As a result, the toxin causes flaccid paralysis by preventing the transmission of nerve impulses to the muscles.

Medical Research and Applications

Research into cobratoxin has revealed potential therapeutic applications, particularly in the field of pain management and neurological disorders. Studies have shown that cobratoxin can act as an analgesic by modulating pain pathways. Additionally, its ability to target specific receptors makes it a candidate for the development of drugs for conditions such as myasthenia gravis and epilepsy.

Toxicity and Treatment

Cobratoxin is highly toxic, and envenomation by a cobra can be fatal if not treated promptly. Symptoms of cobratoxin poisoning include muscle weakness, respiratory failure, and paralysis. Treatment typically involves the administration of antivenom, which contains antibodies that neutralize the toxin. Supportive care, such as mechanical ventilation, may also be necessary in severe cases.

Related Pages

• Naja
• Three-finger toxin
• Nicotinic acetylcholine receptor
• Acetylcholine
• Pain management
• Neurological disorders
• Myasthenia gravis
• Epilepsy
• Antivenom